http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016214995-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32f57a53515b98afbb284cb39a2f17f7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-14 |
| filingDate | 2014-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b27687302d29d329d516f372c071f14 |
| publicationDate | 2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2016214995-A1 |
| titleOfInvention | Substituted thienotriazolodiazapines |
| abstract | The present invention in one embodiment provides a compound of Formula I: (I), or a pharmaceutically acceptable salt thereof, wherein Y 1 , Y 2 and Y 3 are each independently selected from hydrogen and deuterium; R 1 , R 2 , and R 3 are each methyl and are independently substituted with 0 to 3 deuterium; and R 4 is t-butyl and is substituted with 0 to 9 deuterium; provided that if R 1 , R 2 and R 3 are each —CH 3 , and R 4 is —C(CH 3 ) 3 , then at least one of Y 1 and Y 2 is deuterium. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022192097-A1 |
| priorityDate | 2013-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 170.